A Safety Study of NNZ-2566 in Patients With Rett Syndrome
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01703533 |
Recruitment Status :
Completed
First Posted : October 10, 2012
Last Update Posted : February 5, 2018
|
Tracking Information | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | October 4, 2012 | |||||||||||||||
First Posted Date ICMJE | October 10, 2012 | |||||||||||||||
Last Update Posted Date | February 5, 2018 | |||||||||||||||
Study Start Date ICMJE | March 2013 | |||||||||||||||
Actual Primary Completion Date | September 2014 (Final data collection date for primary outcome measure) | |||||||||||||||
Current Primary Outcome Measures ICMJE |
Adverse events [ Time Frame: Through to Day 40 ] Incidence of adverse events (AE), including Serious adverse events (SAE), will be evaluated between the two NNZ-2566 doses and placebo. SAEs will be examined from randomization through to Day 40. AEs will be examined from dosing through to Day 40.
|
|||||||||||||||
Original Primary Outcome Measures ICMJE |
|
|||||||||||||||
Change History | ||||||||||||||||
Current Secondary Outcome Measures ICMJE |
|
|||||||||||||||
Original Secondary Outcome Measures ICMJE |
|
|||||||||||||||
Current Other Pre-specified Outcome Measures |
Pharmacokinetics [ Time Frame: Baseline through to Day 40 ] The following pharmacokinetic measures will be calculated from NNZ-2566 concentrations in whole blood: Tmax, Cmax (peak), Cmin (trough), CAV at steady state, T1/2 and AUC.
|
|||||||||||||||
Original Other Pre-specified Outcome Measures |
Pharmacokinetics [ Time Frame: To be confirmed ] Pharmacokinetic measures will be calculated from NNZ-2566 concentrations in whole blood.
|
|||||||||||||||
Descriptive Information | ||||||||||||||||
Brief Title ICMJE | A Safety Study of NNZ-2566 in Patients With Rett Syndrome | |||||||||||||||
Official Title ICMJE | A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome | |||||||||||||||
Brief Summary | The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett Syndrome in adolescent and adult females. | |||||||||||||||
Detailed Description | Rett Syndrome is a developmental disorder primarily if not exclusively affecting females. The disorder is characterized by apparent normal development in early infancy (6-18 months), followed by a period of regression with onset of systemic and neurological signs. The CNS symptoms of Rett Syndrome include learning disability, autism and epilepsy and these can be severe and highly debilitating. Affected individuals also show signs of autonomic dysfunction, reflected in cardiovascular and respiratory abnormalities. There is no currently effective treatment for Rett Syndrome. This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescent or adult females with Rett Syndrome. The study also will also investigate measures of efficacy during treatment. |
|||||||||||||||
Study Type ICMJE | Interventional | |||||||||||||||
Study Phase ICMJE | Phase 2 | |||||||||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
|||||||||||||||
Condition ICMJE | Rett Syndrome | |||||||||||||||
Intervention ICMJE |
|
|||||||||||||||
Study Arms ICMJE |
|
|||||||||||||||
Publications * | Not Provided | |||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||||||||||||||
Recruitment Information | ||||||||||||||||
Recruitment Status ICMJE | Completed | |||||||||||||||
Actual Enrollment ICMJE |
67 | |||||||||||||||
Original Estimated Enrollment ICMJE |
42 | |||||||||||||||
Actual Study Completion Date ICMJE | September 2014 | |||||||||||||||
Actual Primary Completion Date | September 2014 (Final data collection date for primary outcome measure) | |||||||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
|||||||||||||||
Sex/Gender ICMJE |
|
|||||||||||||||
Ages ICMJE | 16 Years to 45 Years (Child, Adult) | |||||||||||||||
Accepts Healthy Volunteers ICMJE | No | |||||||||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||||||||||||||
Listed Location Countries ICMJE | United States | |||||||||||||||
Removed Location Countries | ||||||||||||||||
Administrative Information | ||||||||||||||||
NCT Number ICMJE | NCT01703533 | |||||||||||||||
Other Study ID Numbers ICMJE | Neu-2566-RETT-001 | |||||||||||||||
Has Data Monitoring Committee | Yes | |||||||||||||||
U.S. FDA-regulated Product | Not Provided | |||||||||||||||
IPD Sharing Statement ICMJE |
|
|||||||||||||||
Current Responsible Party | Neuren Pharmaceuticals Limited | |||||||||||||||
Original Responsible Party | Same as current | |||||||||||||||
Current Study Sponsor ICMJE | Neuren Pharmaceuticals Limited | |||||||||||||||
Original Study Sponsor ICMJE | Same as current | |||||||||||||||
Collaborators ICMJE |
|
|||||||||||||||
Investigators ICMJE |
|
|||||||||||||||
PRS Account | Neuren Pharmaceuticals Limited | |||||||||||||||
Verification Date | January 2018 | |||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |